Pharmaceutical Executive-05-01-2015

Pharmaceutical Executive
Columns

May 19, 2015

Why executives should make the US R&D tax credit part of their planning discussions, by Chai Hoang and Chris Bard.

Pharm Exec’s 9th annual Brand of the Year selection is Gilead Science’s back-to-back cures for HCV. We profile how both drugs reversed expectations around the listless product launch and revived industry reputation for startling breakthrough innovations.

Pharmaceutical Executive

Gilead outlines its key access initiatives for its hepatitis C franchise.

Pharmaceutical Executive
Features

May 08, 2015

What’s new in the growing field of global market access?

Pharmaceutical Executive

Tapping into the fast-growing and lucrative “multicultural” segment requires new and more aggressive approaches to brand planning and consumer engagement.

Pharmaceutical Executive
From the Editor

May 07, 2015

Pharm Exec's 2015 Brand of the Year Sovaldi and Harvoni are huge game-changers for Hepatitis C, but the big-picture impact will come down to how well the market aligns pricing, distribution, and access toward the broader goal of making sure that those patients who need the cure, get the cure.

Pharmaceutical Executive

Inspired by TV’s Mad Men, Julian Upton puts himself into a 1960 executive’s shoes to describe the “ethical pharma” industry of half a century ago

Pharmaceutical Executive

Insurers and payers demand lower prices-along with quality and innovation.

Columns
Pharmaceutical Executive

May 01, 2015

Tactics pharma leaders can implement to stem the continued global threat of counterfeit drugs.

Columns
Pharmaceutical Executive

May 01, 2015

Edging through the complex terrain that is health technology assessment in Europe

Pharmaceutical Executive
Special Sponsored Section

May 01, 2015

Once focused mainly on generic medicines, Korea’s pharma sector has leveraged significant new investments in R&D to transform itself into a true player in the global market-with aspirations as a future top-tier contributor to new medicines innovation.